Bibliographic Details
| Title: |
The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer. |
| Authors: |
Bola, Becky1,2 (AUTHOR), Hoskin, Peter J.3,4 (AUTHOR), Sangar, Vijay2,5 (AUTHOR), Choudhury, Ananya3,4 (AUTHOR) ananya.choudhury@nhs.net |
| Source: |
Cancers. Feb2025, Vol. 17 Issue 4, p628. 14p. |
| Subject Terms: |
*NON-muscle invasive bladder cancer, *DRUG toxicity, *RADIOTHERAPY, *DIFFUSION of innovations, *TERMINATION of treatment, *BCG vaccines, *MEDICAL care, *INVENTORY shortages, *TUMOR markers, *RADIATION-sensitizing agents, *DNA damage, *COMBINED modality therapy, *DRUGS |
| Abstract: |
Simple Summary: Non-muscle invasive bladder cancer (NMIBC) is not currently treated with radiotherapy. However, other bladder cancers are successfully treated with radiotherapy. In this review, we discuss how NMIBC is treated currently and what the advantages and disadvantages of these treatments are. We summarise the recent developments in the treatment of NMIBC and highlight the promise of radiotherapy in this context. We then discuss future treatments for non-muscle invasive bladder cancer and how existing treatments can be made more effective. Global shortages, toxicities, and high levels of incomplete treatment with Bacillus Calmette Guerin (BCG) for non-muscle invasive bladder cancer has resulted in increasing interest in alternative treatments. Radiotherapy is not the standard of care for non-muscle invasive bladder cancer (NMIBC), despite being routinely used in muscle invasive bladder cancer. Modern techniques and advances in technology mean that radiotherapy can be delivered with increased precision in reducing normal tissue damage. Developing novel biomarker approaches, together with combination approaches with radiosensitisers and other systemic treatments, means that radiotherapy could offer greater benefits than current treatments with BCG or surgery. This review summarises the current landscape and future potential of radiotherapy for high-risk NMIBC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
